Atossa Therapeutics Inc

NASDAQ:ATOSUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing medicines for breast cancer, other breast conditions and Covid-19. Its Covid-19 drugs under development, including the AT-H201 program, is for severely ill patients on ventilators, and AT-301 COVID-19 is a nasal spray. Its nasal spray formulation AT-301 is being designed to contain ingredients that can potentially block SARS-CoV-2 viral entry gene proteins in nasal epithelial cells by interfering with spike protein activation by host proteases, by masking receptor binding domains via electrostatic mechanisms, and by providing a generalized mucoadhesive epithelial barrier. AT-H201 program is to develop a therapy to improve lung and function like a chemical vaccine. It is also developing an oral formulation of Endoxifen to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy.

Contact Information

Headquarters

107 Spring StSEATTLE, WA, United States 98104-1005

Phone

206-588-0256

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer

Steven Quay

Chief Financial Officer, General Counsel, Secretary

Kyle Guse

Director

Shu-Chih Chen

Independent Director

Stephen Galli

Independent Director

H. Lawrence Remmel